Amarin Files Definitive Proxy Materials and Mails Letter to Shareholders

Submitted by amarin on Tue, 01/31/2023 - 13:26
Urges Shareholders to Vote “AGAINST” Sarissa’s Proposals on the WHITE Proxy Card Highlights Significant Changes Implemented Over Last 18 Months – New Strategy, New Leadership Team and Significantly Refreshed Board; Transformation Underway with Strong Early Progress Advancing Geographic Expansion

Amarin Files Definitive Proxy Materials and Mails Letter to Shareholders

Submitted by amarin on Tue, 01/31/2023 - 13:25
Urges Shareholders to Vote “AGAINST” Sarissa’s Proposals on the WHITE Proxy Card Highlights Significant Changes Implemented Over Last 18 Months – New Strategy, New Leadership Team and Significantly Refreshed Board; Transformation Underway with Strong Early Progress Advancing Geographic Expansion

Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved By Medsafe In New Zealand

Submitted by amarin on Fri, 01/27/2023 - 13:45
Marks 7th Regulatory Approval for VASCEPA®/VAZKEPA® Franchise in Key International Markets Since 2022 DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Medsafe in New Zealand has granted approval to VAZKEPA (icosapent

Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved By Medsafe In New Zealand

Submitted by amarin on Fri, 01/27/2023 - 13:45
Marks 7th Regulatory Approval for VASCEPA®/VAZKEPA® Franchise in Key International Markets Since 2022 DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Medsafe in New Zealand has granted approval to VAZKEPA (icosapent

Amarin to Present at SVB Securities Global Biopharma Conference

Submitted by amarin on Fri, 01/27/2023 - 13:00
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the SVB Securities Global Biopharma Conference.

Amarin Responds to Inaccurate and Misleading Statement by Sarissa

Submitted by amarin on Thu, 01/19/2023 - 12:00
-- Board Refreshment Process Has Been Comprehensive, Independent and Transparent; Sarissa’s Candidates Are Not Qualified Versus Recently Appointed Board Members -- -- Amarin Recognizes Shareholder Frustration with U.S. IP Loss And Has Taken Decisive Action with a New Strategy, New Team and New

Amarin Responds to Inaccurate and Misleading Statement by Sarissa

Submitted by amarin on Thu, 01/19/2023 - 12:00
-- Board Refreshment Process Has Been Comprehensive, Independent and Transparent; Sarissa’s Candidates Are Not Qualified Versus Recently Appointed Board Members -- -- Amarin Recognizes Shareholder Frustration with U.S. IP Loss And Has Taken Decisive Action with a New Strategy, New Team and New

Amarin Comments on Sarissa’s Notice to Call a Special Meeting of Amarin Shareholders

Submitted by amarin on Wed, 01/11/2023 - 21:34
Highlights Significant Board Refreshment, Operational and Financial Improvements and Engagement with Sarissa Capital Management DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) (“Amarin” or the “Company”) today confirmed receipt of a

Amarin Comments on Sarissa’s Notice to Call a Special Meeting of Amarin Shareholders

Submitted by amarin on Wed, 01/11/2023 - 21:34
Highlights Significant Board Refreshment, Operational and Financial Improvements and Engagement with Sarissa Capital Management DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) (“Amarin” or the “Company”) today confirmed receipt of a

Amarin Provides Preliminary Fourth Quarter and Full Year 2022 Revenue and Cash Position and Priorities for 2023

Submitted by amarin on Tue, 01/10/2023 - 12:15
-- Company Delivers Fourth Consecutive Quarter of U.S. Revenue Stabilization, Positive Fourth Quarter Cash Flow and Continued Progress on European Reimbursements -- -- Amarin to Present at 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023 -- DUBLIN, Ireland and BRIDGEWATER, N.J.,